Is Armata Pharmaceuticals, Inc. overvalued or undervalued?

As of 1 October 2023, Armata Pharmaceuticals, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a return on equity (ROE) of 12%.
In comparison to its peers, such as Moderna, Inc. with a P/E ratio of 18.5 and Gilead Sciences, Inc. with a P/S ratio of 4.0, Armata appears to be trading at a discount. This valuation is further supported by the recent stock performance, where Armata has outperformed the Sensex, reinforcing the attractiveness of its current price.